Working to Eradicate Gynecologic Cancers

Beth Y. Karlan, MD

Director, Women's Cancer Program
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Institute
8700 Beverly Blvd., Suite 290W
Los Angeles, CA
USA 90048


Biographical Sketch:
As a physician and translational researcher, Dr. Beth Y. Karlan has more than 20 years experience in gynecologic oncology and an extensive background scientific publication. She is Editor-In-Chief of both the journal Gynecologic Oncology and the journal Gynecologic Oncology Case Reports. She has authored more than 200 publications and edited thousands submitted by colleagues and those she has mentored. Dr. Karlan’s research submissions have been granted funding from The NIH, NCI, DOD and American Cancer Society and many private and public foundations. She is widely recognized as a leading expert in the field of gynecologic oncology and her efforts have helped shape the current standards of care for the specialty."

Papers:
144 Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project 278 Does digoxin improve ovarian cancer survival? A SEER-Medicare database analysis 344 Morbidity of triple modality therapy in the management of early stage cervical cancer 443 Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer 513 Co-culture of human induced pluripotent stem cells (iPSCs) with human fallopian tube epithelium (FTE) induces Pax8 and CK7 expression: initial steps in modeling fallopian tube epithelium to study serous carcinogenesis Epidemiologic predictors of pre-treatment CA125 in women with ovarian cancer